



# PIPELINE INSIGHTS REPORT

## DRUGS TO WATCH



### Mavacamten

Mavacamten would be the first disease-specific medication to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM). If approved, mavacamten will be limited to patients with **symptomatic, obstructive forms of HCM**.

Trial results for mavacamten were promising. While the safety profile for mavacamten appears reasonable, we still lack long-term data on cardiovascular effects.

While no price is available, industry analysts forecast an annual cost of **\$75,000**. This contrasts with an Institute for Clinical and Economic Review (ICER) estimated health-benefit price of \$12,000 and \$15,000 per year.



### Vutrisiran

Vutrisiran for treating of a rare inherited condition (polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR). While the target population is small (~2,000 globally), this is a high-cost category. Existing drugs cost about \$500,000 per year.

If approved, vutrisiran would provide another treatment option for hATTR. Its' competitive advantage would be quarterly via subcutaneous injection vs. intravenous infusion every three weeks.

No pricing information is available.



### Tirzepatide

Tirzepatide for managing type 2 diabetes. Almost 80% of those with type 2 diabetes may also have obesity. Tirzepatide combines an older and newer mechanism that may result in greater effects on both glucose and body weight.

Tirzepatide would compete against existing treatments such as insulin and Ozempic®. But several drugs are effective and also offer proven cardiovascular (CV) outcomes. CV outcomes for tirzepatide are not expected until 2025.

Prices not available but the wholesale acquisition cost for Ozempic is approximately \$10,000 per year.



## Tapinarof

Tapinarof is a topical treatment for plaque psoriasis. Plaque psoriasis is the most common form of psoriasis, and affects approximately six million people in the U.S.

In trials tapinarof demonstrated superiority over placebo.

Tapinarof would compete against existing first-line agents like corticosteroids and vitamin D analogs, which are available generically, but there is no head-to-head trial data comparing tapinarof against them.

Price is not yet available. For reference, the wholesale acquisition cost for Wyzora®, a branded combination cream containing a vitamin D analog and corticosteroid, is approximately \$1,000 per 30 days.

**Tapinarof is just one of four new plaque psoriasis therapies that may be approved by the end of this year. In our Market Trends section, we explore this large and growing category in greater detail.**



[optum.com/optumrx](https://optum.com/optumrx)

OptumRx is a pharmacy care services company helping clients and approximately 60 million members achieve better health outcomes and lower overall costs through innovative prescription drug benefits services. OptumRx is part of Optum®, a leading information and technology-enabled health services business dedicated to making the health system work better for everyone. For more information, visit [optum.com/optumrx](https://optum.com/optumrx).

All Optum trademarks and logos are owned by Optum, Inc. All other trademarks are the property of their respective owners.

© 2022 Optum, Inc. All rights reserved. ORX2582290\_220316